Hypothesis

Simultaneously enhancing vagal afferent signaling and delivering microbiota-derived butyrate to the gut will synergistically break the bidirectional inflammaging cycle more effectively than either approach alone, by reducing CNS‑driven sympathetic outflow that sustains dysbiosis and restoring gut‑derived anti‑inflammatory metabolites that protect the blood‑brain barrier and microglia.

Rationale

Aging-related gut dysbiosis elevates LPS and reduces SCFAs, driving neuroinflammation via impaired vagal signaling to the hippocampus[2]. Conversely, CNS inflammation heightens sympathetic activity and alters gut immunity, reinforcing microbial imbalance[1]. Butyrate suppresses monocyte inflammation, strengthens tight junctions, and inhibits Aβ fibrillization[4]. Vagal activation restores hippocampal BDNF and reverses memory deficits[2]. However, each monotherapy leaves the opposite arm of the loop intact: vagal stimulation alone does not replenish SCFAs, while butyrate supplementation does not directly dampen CNS‑originated sympathetic signals that perpetuate dysbiosis.

We propose that age‑related decline in hippocampal α7 nicotinic acetylcholine receptor (α7nAChR) signaling diminishes the cholinergic anti‑inflammatory pathway to the gut, leading to elevated TNF‑α that shifts microbial composition toward LPS‑producers. Restoring α7nAChR signaling (via vagal afferent boost) and supplying butyrate (via a targeted prodrug that releases in the colon) should therefore act on both sides of the loop: vagal input reduces sympathetic drive to the gut, while butyrate rectifies barrier function and microglial activation.

Predictions

1. Aged mice receiving combined vagal stimulation (e.g., transcutaneous auricular VNS) and colonic butyrate prodrug will show a greater reduction in plasma LPS and circulating TNF‑α than either treatment alone.
2. Hippocampal BDNF and synaptic markers (PSD‑95, synaptophysin) will increase to youthful levels only in the combined group.
3. Cognitive performance in the Morris water maze will improve significantly more in the combined group, with effect size exceeding the sum of individual monotherapies (synergy).
4. 16S rRNA sequencing will reveal a restored abundance of butyrate‑producing taxa (e.g., Faecalibacterium, Roseburia) and a decrease in LPS‑rich taxa only in the combined condition.

Experimental Design

• Subjects: 24‑month-old C57BL/6J mice (n=12 per group). Groups: (1) sham VNS + vehicle, (2) VNS + vehicle, (3) sham VNS + butyrate prodrug, (4) VNS + butyrate prodrug.
• Interventions: VNS delivered 30 min/day, 5 days/week for 8 weeks; butyrate prodrug formulated for colonic release administered via drinking water daily.
• Outcomes: Plasma LPS (ELISA), cytokines (TNF‑α, IL‑6, IL‑10), hippocampal BDNF (Western blot), memory performance (Morris water maze probe trial), fecal SCFA profiling (GC‑MS), microbiota composition (16S rRNA sequencing).
• Statistical analysis: Two‑way ANOVA with factors VNS and butyrate, testing for interaction (synergy). Falsifiability: If the interaction term is non‑significant and combined group does not outperform the best monotherapy, the hypothesis is rejected.

Potential Outcomes and Interpretation

• Synergistic improvement across biochemical, microbial, and cognitive readouts would support the notion that the inflammaging loop is best collapsed by concurrent modulation of CNS‑to‑gut signaling and gut‑derived metabolite replenishment.
• Additive but not synergistic effects would suggest that the two arms operate largely in parallel, implying that targeting either side suffices for maximal benefit.
• No improvement in the combined group would challenge the premise that vagal signaling and butyrate are key mediators of the loop, prompting re‑evaluation of alternative pathways (e.g., mucosal immunity, enteroendocrine signaling).

This hypothesis is directly testable with current tools and offers a clear path toward combinatorial interventions that could overcome the limitations of monotherapies in age‑related cognitive decline.